385 related articles for article (PubMed ID: 19286905)
1. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.
Choy E; Sattar N
Ann Rheum Dis; 2009 Apr; 68(4):460-9. PubMed ID: 19286905
[TBL] [Abstract][Full Text] [Related]
2. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
[TBL] [Abstract][Full Text] [Related]
3. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.
Steiner G; Urowitz MB
Semin Arthritis Rheum; 2009 Apr; 38(5):372-81. PubMed ID: 18395771
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
[TBL] [Abstract][Full Text] [Related]
5. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
Dahlqvist SR; Engstrand S; Berglin E; Johnson O
Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
[TBL] [Abstract][Full Text] [Related]
6. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
[TBL] [Abstract][Full Text] [Related]
7. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
García-Gómez C; Nolla JM; Valverde J; Narváez J; Corbella E; Pintó X
Eur J Clin Invest; 2008 Sep; 38(9):686-92. PubMed ID: 18837746
[TBL] [Abstract][Full Text] [Related]
8. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
[TBL] [Abstract][Full Text] [Related]
9. Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey.
Choi HK; Seeger JD
J Rheumatol; 2005 Dec; 32(12):2311-6. PubMed ID: 16331755
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between blood lipid spectrum and activity of the disease in patients with rheumatoid arthritis].
Shirinskiĭ IV; Zheltova OI; Shirinskiĭ VS; Kozlova VA
Klin Med (Mosk); 2008; 86(12):40-3. PubMed ID: 19227308
[TBL] [Abstract][Full Text] [Related]
11. Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists.
Motivala SJ; Khanna D; FitzGerald J; Irwin MR
Arthritis Rheum; 2008 Feb; 58(2):376-83. PubMed ID: 18240230
[TBL] [Abstract][Full Text] [Related]
12. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
Toms TE; Panoulas VF; Douglas KM; Nightingale P; Smith JP; Griffiths H; Sattar N; Symmons DP; Kitas GD
Angiology; 2011 Feb; 62(2):167-75. PubMed ID: 20682616
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
14. Atherogenic lipid profiles in rheumatoid arthritis.
White D; Fayez S; Doube A
N Z Med J; 2006 Aug; 119(1240):U2125. PubMed ID: 16924276
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-α inhibitor use is not associated with lipid changes in rheumatoid arthritis.
Bili A; Morris SJ; Sartorius JA; Kirchner HL; Antohe JL; Dancea S; Wasko MC
J Rheumatol; 2012 May; 39(5):946-8. PubMed ID: 22467937
[TBL] [Abstract][Full Text] [Related]
16. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
van Sijl AM; Peters MJ; Knol DL; de Vet RH; Sattar N; Dijkmans BA; Smulders YM; Nurmohamed MT
Semin Arthritis Rheum; 2011 Dec; 41(3):393-400. PubMed ID: 21665247
[TBL] [Abstract][Full Text] [Related]
17. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
Liao KP; Playford MP; Frits M; Coblyn JS; Iannaccone C; Weinblatt ME; Shadick NS; Mehta NN
J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637346
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans.
Birjmohun RS; van Leuven SI; Levels JH; van 't Veer C; Kuivenhoven JA; Meijers JC; Levi M; Kastelein JJ; van der Poll T; Stroes ES
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1153-8. PubMed ID: 17303780
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
20. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better.
Peters MJ; Voskuyl AE; Sattar N; Dijkmans BA; Smulders YM; Nurmohamed MT
Int J Clin Pract; 2010 Sep; 64(10):1440-3. PubMed ID: 20716150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
